Moreover, combined CDK4/6i and endocrine therapy is currently being tested in the adjuvant setting (NCT02513394, NCT03155997 and NCT03701334) and is expected to also be approved for treatment of primary ER+ breast cancer. Here, ESR1 is linked to breast cancer.